10x Genomics, Inc. research snapshot
TXG AI stock analysis reads 10x Genomics as a single-cell and spatial genomics platform nearing GAAP breakeven, with positive TTM EBITDA and free cash flow, after the launch of its Atera spatial whole transcriptome platform. At the August 3, 2026 data cutoff, the July 31, 2026 close was $47.27, implying a market capitalization near $6.00 billion, which is above the $41.54 average analyst price target. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$47.27
Market cap
$6.00 billion
AI score
58 / 100
Rating
Near-profitability inflection but priced above the average analyst target
Trend status
Uptrend intact near a 52-week high after a roughly 240% twelve-month rally; TTM free cash flow and net income keep improving while the revenue multiple trades above the $41.54 average analyst price target
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | 10x Genomics sells instruments, consumables, and software for single-cell and spatial genomics analysis. Customers pay to measure biology at cellular and tissue resolution for academic, pharmaceutical, AI model, and translational research. | High |
| Moat | Technology leadership in single-cell and spatial transcriptomics is reinforced by patents, proprietary chemistry and bioinformatics, a large installed base of Chromium and Xenium instruments, and workflow lock-in through consumables, software, and the new Atera platform. | Medium-high |
| Management | Co-founder and CEO Serge Saxonov has led the company to near-profitability and through its largest product launch, Atera. The key test is whether revenue growth re-accelerates as guided for 2027 and whether margin and cash-flow gains hold under competitive pressure. | Medium |
| Financial trend | FY2025 revenue was $642.82 million, up 5.2%. Q1 2026 revenue was $150.8 million, up 9% excluding prior-year settlement revenue. TTM net loss narrowed to $22.66 million from $43.54 million in FY2025 and $182.63 million in FY2024, and TTM free cash flow was $122.18 million. | High |
| Valuation | At the latest $47.27 close, TXG trades at roughly 9.4x trailing revenue, 49x trailing free cash flow, and 7.5x book value. The $41.54 average analyst target sits below the current price, reflecting how far the stock has run ahead of sell-side estimates. | Medium |
| Technical trend | The stock has rallied from a 52-week low of $11.16 to a 52-week high of $50.34 set intraday on July 31, 2026, then closed at $47.27. The trend is up but extended, and confirmation of the $50.34 breakout matters. | Medium |
| Risk level | Risk is elevated and includes Atera cannibalizing Xenium and Visium sales, competition from Illumina, Bruker, NanoString, and emerging spatial platforms, research funding cycles, instrument placement lumpiness, customer concentration, and short interest near 12.8% of shares outstanding. | High |
| AI confidence | Reported financials, share count, cash, and market-cap math are well-supported. Share-price outcomes are not reliably predictable for a high-multiple life-sciences tools stock trading above its average analyst target. | High data confidence |
| Investment certainty | Low to medium certainty. The operating trajectory is improving, but the investment case depends on the 2027 Atera ramp, revenue re-acceleration, durable margin expansion, and continued premium multiple support. | Low to medium |
TXG AI stock forecast
The TXG AI stock forecast uses sales and free-cash-flow scenarios around the latest $47.27 close and the FY2026 revenue guidance of $600 million to $625 million. 10x Genomics still reports a small GAAP loss, so a mechanical EPS target is not useful. The scenario ranges below are conditional, not price promises.
$52 to $62
More likely if the August 6 Q2 2026 report confirms strong Atera pre-orders, FY2026 guidance is maintained, spatial consumables keep growing at double digits, gross margin holds near the high-60s%, and AI-driven data demand from partners such as Bioptimus and the Chan Zuckerberg Biohub expands the order book into 2027.
$38 to $48
More likely if 10x delivers the $600 million to $625 million FY2026 guidance, Atera shipments begin as guided in the second half with roughly 40 units placed, and the revenue multiple eases toward the $41.54 average analyst target as the stock consolidates after its large rally.
$26 to $36
More likely if Atera cannibalizes Xenium and Visium instrument sales faster than expected, research funding stays constrained, gross margin dips below the mid-60s% outlook, FY2027 growth disappoints, or the premium multiple compresses sharply from current levels.
TXG AI technical analysis
TXG AI technical analysis shows a strong uptrend that is extended near the 52-week high after a roughly 240% twelve-month rally, as of the July 31, 2026 close. The stock set a 52-week high of $50.34 intraday on July 31 before closing at $47.27, leaving the $50.34 level as the key overhead test. Support sits near the $46.25 July 31 day low, then around $44, with the 50-day moving average near $36.59 as the first major trend reference below price.
| Level | Value | Why it matters |
|---|---|---|
| Latest available close | $47.27 | StockAnalysis/CBOE July 31, 2026 close, down 4.37% from the $49.43 prior close. After-hours showed $46.54. The August 3 research cutoff meant markets were closed during analysis. |
| Near support | $46.25 | The July 31 daily range low. A sustained close below this level would be the first sign that the rally is stalling after the failed attempt to hold above $50. |
| Support zone | $42 to $44 | The late-July breakout area and the former resistance near the July 10 close of $42.73. This zone is now the first meaningful support cluster below the July 31 range. |
| Major moving average | 50-day near $36.59, 200-day near $23.36 | The 50-day moving average has been rising and is the first major trend reference below price. The 200-day average sits well below current price, which is constructive for the long-term trend. |
| Resistance | $50.34 | The 52-week high set intraday on July 31, 2026. A clean break above this level with volume would open a new high zone and extend the uptrend. |
| Momentum | Strong but extended | The 14-day RSI was near 62 at the July 31 snapshot. After a roughly 240% twelve-month rally, the stock appears technically extended, which argues for disciplined entries near support rather than chasing. |
| Volume | Near the 20-day average | July 31 volume was about 2.87 million shares, roughly in line with the 20-day average near 2.85 million. The August 6 Q2 earnings report is the next major volume catalyst. |
| Volatility | Elevated (beta 2.04) | With a 5-year monthly beta of 2.04, TXG is roughly twice as volatile as the market. Position sizing should reflect this. |
| Invalidation | Close below $44 | A decisive close below the $44 support zone would suggest the rally is losing momentum and could target the 50-day moving average near $36.59. That should trigger a review of the technical and operating thesis. |
TXG AI trading strategy
The TXG AI trading strategy is a rules-based framework for a high-beta life-sciences tools stock trading above its average analyst target and approaching a key resistance test. It is not personal advice and should be paired with the August 6 Q2 2026 earnings report, live prices, product cycle updates, competition tracking, position sizing, and an independent review of risk.
Watch for TXG to reclaim and hold above the $50.34 52-week high with above-average volume, while the August 6 Q2 report confirms Atera order momentum and FY2026 guidance is maintained.
A sustained close below $46.25 would weaken the near-term breakout structure. A break below $44 should prompt a broader review of technical and fundamental assumptions before any new long.
If TXG pulls back toward the $42 to $44 support zone or toward the 50-day moving average near $36.59 without a change in the competitive, product, or financial outlook, compare the pullback with the latest Atera pre-order data, instrument placements, and consumable revenue trends.
Do not treat every pullback as a buying opportunity. A research funding downturn, competitive product win, Atera cannibalization of spatial sales, or guidance cut can change the thesis quickly.
Track the August 6 Q2 2026 earnings report, FY2026 guidance of $600 million to $625 million, Atera unit placements of roughly 40 in the second half, gross margin versus the mid-60s% outlook, spatial consumables growth, cash near $540 million, and competitive announcements from Illumina, Bruker, NanoString, and emerging spatial platforms.
Reduce confidence if revenue growth turns negative excluding one-time items, Atera cannibalizes existing spatial sales without offsetting growth, gross margin contracts below the mid-60s%, or management delays the path to GAAP profitability.
Investment research summary
10x Genomics converts proprietary microfluidics, chemistry, and bioinformatics into recurring consumable and instrument revenue by enabling researchers to analyze gene expression at single-cell and spatial resolution, with the Atera platform adding whole transcriptome spatial analysis at scale.
The moat is built from patented microfluidics and chemistry, a large installed base of Chromium, Xenium, and now Atera instruments, workflow-dependent consumable and software revenue, accumulated biological data, and brand recognition in single-cell and spatial genomics.
The thesis fails if Atera cannibalizes Xenium and Visium sales faster than new demand grows, if competitors such as Illumina, Bruker, or NanoString erode market share, if NIH and academic research funding tightens, if the instrument replacement cycle disappoints, if gross margin contracts, or if the premium multiple compresses.
Founder-CEO Serge Saxonov has led the company to near-profitability, grown cash by over $100 million in a year, and launched Atera, described as the largest product introduction in company history. The capital-allocation question is whether R&D and commercial spending convert into durable revenue growth and sustained GAAP profitability.
Single-cell and spatial genomics is a growing field within life-sciences research, and AI model building is a new structural demand driver. Partners such as Bioptimus, the Chan Zuckerberg Biohub, Xaira, and the Arc Institute are using 10x platforms to generate large biological datasets, while clinical diagnostics remains a longer-term optionality.
TXG trades at roughly 9.4x trailing revenue and 49x trailing free cash flow, above the $41.54 average analyst target. Margin of safety is limited given the modest FY2026 growth outlook and competitive risk, and improves only if the 2027 Atera ramp re-accelerates growth and margins hold.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TXG price | $47.27 at July 31, 2026 close, after-hours $46.54 | StockAnalysis (CBOE real-time quote) | August 3, 2026 |
| Market capitalization | $6.00 billion, verified as $47.27 x 126.96 million shares | financial_rigor.py market-cap verification and StockAnalysis | August 3, 2026 |
| Revenue (TTM) | $638.78 million, up 2.3% year over year | StockAnalysis (S&P Global Market Intelligence) | August 3, 2026 |
| FY2025 revenue | $642.82 million, up 5.24% from $610.79 million in FY2024 | StockAnalysis (S&P Global Market Intelligence) | August 3, 2026 |
| Q1 2026 revenue | $150.8 million, up 9% year over year excluding prior-year settlement revenue | 10x Genomics Q1 2026 earnings call transcript | August 3, 2026 |
| Net income (TTM) | -$22.66 million, improving from -$43.54 million in FY2025 and -$182.63 million in FY2024 | StockAnalysis (S&P Global Market Intelligence) | August 3, 2026 |
| Gross margin (TTM) | 69.68%, with Q1 2026 gross margin near 70% | StockAnalysis and 10x Genomics Q1 2026 earnings call | August 3, 2026 |
| Cash and debt at March 31, 2026 | $539.85 million cash and investments; $81.39 million total debt | StockAnalysis balance sheet | August 3, 2026 |
| Free cash flow (TTM) | $122.18 million (operating cash flow $127.82 million less capex $5.64 million) | StockAnalysis cash flow | August 3, 2026 |
| FY2026 revenue guidance | $600 million to $625 million, 0% to 4% growth over FY2025 excluding settlement revenue | 10x Genomics Q1 2026 earnings call, May 7, 2026 | August 3, 2026 |
| Price to sales ratio | 9.39x TTM revenue (financial_rigor.py, $6.00B / $638.78M) | StockAnalysis statistics and financial_rigor.py calculation | August 3, 2026 |
| Shares outstanding | 126.96 million | StockAnalysis share statistics | August 3, 2026 |
| 52-week range | $11.16 to $50.34 | StockAnalysis (CBOE) | August 3, 2026 |
| Beta | 2.04 | StockAnalysis statistics | August 3, 2026 |
| Analyst consensus target | Buy from 16 analysts, $41.54 average, $40 median, range $25 to $50 (Canaccord $50, TD Cowen $47, Citi $45, Barclays and Leerink $40, JPMorgan $38, Morgan Stanley $37) | StockAnalysis forecast / S&P Global and TipRanks | August 3, 2026 |
| Short interest | 16.25 million shares, 12.80% of shares outstanding | StockAnalysis short interest | August 3, 2026 |
This TXG page is an informational research tool, not investment advice or a recommendation to buy or sell. Forecast ranges are scenarios based on available data and may be wrong if financial results, Atera shipment timing, competition, research funding, product adoption, regulation, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
